TheraVida to conduct more studies of Tolenix after reporting positive Phase II data
This article was originally published in Scrip
Executive Summary
TheraVida said it intends to conduct additional international clinical trials of its lead product candidate, Tolenix (THVD-201), for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI) having reported positive Phase II data for the drug.